1-Acetyl-1-ethyl-2,2-dimethylhydrazin | 50599-38-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 1-Acetyl-1-ethyl-2,2-dimethylhydrazin
• 英文别名: N-ethyl-N',N'-dimethylacetohydrazide
• CAS: 50599-38-7
• 化学式: C₆H₁₄N₂O
• 分子量: 130.19
• InChiKey: JIZDSKTWESBDLV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  23.6
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Pyridinone Pyrazole Urea and Pyrimidinone Pyrazole Urea Derivatives
  申请人：Devadas Balekudru

  公开号：US20090270350A1

  公开（公告）日：2009-10-29

  This invention is directed generally to substituted pyridinone and pyrimidinone compounds that generally inhibit p38 kinase, TNF, and/or cyclooxygeπase activity. Such substituted pyridinone and pyrimidinone compounds include compounds generally corresponding in structure to the following formula: wherein Z, n, R 1 , R 2a , R 2b , R 2c , R 2d , R 2e , R 3a , R 3b , R 3c , R 3d , R 4 , R 5 , R 6 , R 7a , R 7b , R 7c , R 7d and R 7e are as defined in this specification. This invention also is directed to compositions of such substituted pyridinones and pyrimidinones (particularly pharmaceutical compositions), and methods for treating disorders (typically pathological disorders) associated with p38 kinase activity, TNF activity, and/or cyclooxygenase-2 activity.

  本发明通常涉及取代的吡啶酮和嘧啶酮化合物，它们通常抑制p38激酶、TNF和/或环氧合酶活性。这些取代的吡啶酮和嘧啶酮化合物包括通常对应于以下结构公式的化合物：其中Z、n、R1、R2a、R2b、R2c、R2d、R2e、R3a、R3b、R3c、R3d、R4、R5、R6、R7a、R7b、R7c、R7d和R7e如本说明书所定义。本发明还涉及这些取代的吡啶酮和嘧啶酮（特别是药物组成物）的组成物，以及用于治疗与p38激酶活性、TNF活性和/或环氧合酶-2活性相关的疾病（通常是病理性疾病）的方法。
• -SECRETASE INHIBITORS
  申请人：Takeda Chemical Industries, Ltd.

  公开号：EP1283039A1

  公开（公告）日：2003-02-12

  An excellent β secretase inhibitor is provided, which comprises a compound of the general formula: wherein Ar is an aromatic group; X is a divalent group selected from -O-, -S-, -CO-, -SO-, -SO2-, -NR8-, -CONR8-, -SO2NR8-, and -COO- (wherein R8 is hydrogen, etc.), a divalent C1-6 aliphatic hydrocarbon group which may contain one or two of these divalent groups, or a bond; Y is a divalent group selected from -O-, -S-, -CO-, -SO-, -SO2-, -NR8-, -CONR8-, -SO2NR8-, and -COO-, or a divalent C1-6 aliphatic hydrocarbon group which may contain one or two of these divalent groups; R1 and R2 are hydrogen, a hydrocarbon group, etc., respectively; and A is a ring which may be further substituted, or a salt thereof.

  本发明提供了一种优异的β分泌酶抑制剂，它由通式如下的化合物组成： 其中 Ar 是芳香族基团；X 是二价基团，选自-O-、-S-、-CO-、-SO-、-SO2-、-NR8-、-CONR8-、-SO2NR8-和-COO-（其中 R8 是氢等）；二价 C1-6 脂肪族烃基团，可包含一个或两个这些二价基团。Y是选自-O-、-S-、-CO-、-SO-、-SO2-、-NR8-、-CONR8-、-SO2NR8-和-COO-的二价基团，或可包含一个或两个这些二价基团的二价 C1-6 脂肪族烃基；R1 和 R2 分别是氢、烃基等、分别为氢、烃基等；A 为可进一步取代的环或其盐。
• Prodrugs of NH-Acidic Compounds: Ester, Carbonate, Carbamate and Phosphonate Derivatives
  申请人：Alkermes Pharma Ireland Limited

  公开号：US20170196848A1

  公开（公告）日：2017-07-13

  The invention provides a method of sustained delivery of a lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug by administering to a patient an effective amount of a prodrug compound of the invention wherein upon administration to the patient, release of the parent drug from the prodrug is sustained release. Prodrug compounds suitable for use in the methods of the invention are labile conjugates of parent drugs that are derivatized through carbonyl linked prodrug moieties. The prodrug compounds of the invention can be used to treat any condition for which the lactam, imide, amide, sulfonamide, carbamate or urea containing parent drug is useful as a treatment.
• [EN] PYRIDINONE PYRAZOLE UREA AND PYRIMIDINONE PYRAZOLE UREA DERIVATIVES<br/>[FR] DERIVES PYRIDINONE-PYRAZOLE-UREE ET PYRIMIDINONE-PYRAZOLE-UREE
  申请人：PFIZER PROD INC

  公开号：WO2007091176A1

  公开（公告）日：2007-08-16

  [EN] This invention is directed generally to substituted pyridinone and pyrimidinone compounds that generally inhibit p38 kinase, TNF, and/or cyclooxygepase activity. Such substituted pyridinone and pyrimidinone compounds include compounds generally corresponding in structure to the following formula: wherein Z, n, R¹, R^2a, R^2b, R^2c, R^2d, R^2e, R^3a, R^3b R^3c, R^3d, R⁴, R⁵, R⁶, R^7a, R^7b, R^7c, R^7d and R^7e are as defined in this specification. This invention also is directed to compositions of such substituted pyridinones and pyrimidinones (particularly pharmaceutical compositions), and methods for treating disorders (typically pathological disorders) associated with p38 kinase activity, TNF activity, and/or cyclooxygenase-2 activity.
  [FR] L'invention concerne de manière générale des composés pyridinone et pyrimidinone substitués qui ont pour action générale d'inhiber l'activité de la kinase p38, du facteur de nécrose tumorale TNF et/ou de la cyclooxygénase. De tels composés incluent des composés dont la structure répond de manière générale à la formule suivante, dans laquelle Z, n, R¹, R^2a, R^2b, R^2c, R^2d, R^2e, R^3a, R^3b R^3c, R^3d, R⁴, R⁵, R⁶, R^7a, R^7b, R^7c, R^7d et R^7e sont tels que définis dans la description. L'invention concerne également des compositions comprenant lesdits composés pyridinone et pyrimidinone substitués (en particulier des compositions pharmaceutiques) ainsi que des procédés visant à traiter des troubles (typiquement des troubles pathologiques) associés à l'activité de la kinase p38, du TNF et ou de la cyclooxygénase-2.